anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An immuno-stimulating glycopeptide, obtd. from the cell wall of an immunity stimulating bacterium of the Actinomycetaceae or Mycobacteriaceae genus (Prevot's classification), is purified by removing nucleic acids and Cytoplasma proteins, pref. by treating the whole bacterial cells by 2-phase extraction using aq. and aryl alcohol contg. phases. A novel immuno-stimulating glycopeptide (I), obtd. from cell walls of a suitable immuno-stimulating Actinomycetaceae or Mycobacteriacease bacterium, is insol. in water, physiolocial saline, MeOH, EtOH, PhOH, CHCL3, dioxan, pyridine, DMF, diethylene glycol and hexane; is free of nuclei acids; has IR absorptions at 1550 and 1660 cm -1 (due to peptide) and at 950-1100 cm -1 (max. 1050-1070 cm -1) (due to carbohydrate); has little or no lipid absorption at 2850-2950 cm -1; and on i.v. admnistration increases the wt. of the liver and spleen of mice, and increases the life expectancy of mice infected with tumours. (I) increases the resistance of animals and birds to tumours and various disease stimulants, by inhibiting growth and/or preventing the start of growth. (I) may be used therapeutically or prophylactically against tumours such as leukaemia, Hodgknson's disease, carcinoma of the lungs, bladder or breast, melanoma and Burkitt's lymphoma, against bacterial diseases due to Bordetella pertussis or Brucella abortus, or against parasitic protozoal diseases e.g. malaria.
PURPOSE: A rice bran extract for preventing or treating sleep disorder, anxiety, or depression is provided to reduce sleep latency and to increase non-REM sleep without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating sleep disorder, anxiety, or depression contains rice bran extract as an active ingredient. The extract is prepared using water, organic solvent, or a mixture thereof. The organic solvent is low carbon number alcohol, hexane, acetone, ethyl acetate, chloroform, or diethyl ether. The extract is also a fraction prepared by fractioning the organic solvent extract with a second organic solvent. A food composition for preventing or treating sleep disorder, anxiety, or depression contains the extract as an active ingredient.
CM93 is a third-generation, covalent/irreversible, brain penetrant small molecule Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor. It is not a substrate of p-glycoprotein or breast cancer resistance protein (bcrp) and is a mild inhibitor of bcrp. It is a potent inhibitor of EGFR mutations but also has activity against wild type EGFR.

This first-in-human phase I trial will evaluate the safety, tolerability, and pharmacokinetics (PK) of CM93 and determine the recommended Phase 2 dose (RP2D) for further evaluation using a 3+3 design (Part 1). Once the RP2D has been determined 12 additional patients will be treated in a dose expansion cohort to confirm the safety and tolerability of the selected dose (Part 2). Subsequent to the phase I trial a window-of-opportunity surgical trial will initiate. Tumor from both contrast enhancing and non-contrast enhancing areas of patients who received CM93 before surgery will be resected and evaluated to determine if therapeutic concentrations of the drug are achieved. Pharmacodynamic studies will be conducted in tumor tissue from patients who received CM93 before surgery and the patients who did not receive drug before surgery to determine if there is adequate inhibition of EGFR. After recovery from surgery all 30 patients will receive CM93 until progression, development of unacceptable toxicity, or withdrawal of consent and preliminary evidence of activity will be obtained.
Myopia is becoming a global public health burden which is believed to have a multifactorial etiology. The relationship between heterophoria and refraction remains controversial. We describe the association of refraction and axial length (AL) with heterophoria in a large population-based study of school-aged Chinese children. Eleven thousand thirteen elementary school children grades 1-6, were included in this school-based, cross-sectional study. Near phoria data was quantified by using Maddox rod test and prism at 33 cm. Children in each grade level were sorted into three groups based upon phoria: 1) those with more than six prism diopters (PD) exophoria, 2) those with zero to six PD exophoria, and 3) those with any amount of esophoria. Autorefraction was measured by autorefractor (Topcon KR8900, Japan) and AL was measured by Optical Biometer AL-Scan (Nidek AL-Scan, Japan). A generalized additive model (GAM) was applied with a Gaussian link to explore the association between the refractive error or axial length and heterophoria. An additional age-adjusted model was also employed for analysis.
The current S3 guideline, "Positioning Therapy and Mobilization of Critically Ill Patients in Intensive Care Units", introduces methodological changes and substantive updates compared to the previous version. Additionally, new evidence-based insights with specified PICO questions have been integrated, aiming for a more precise application of recommendations in clinical practice and thus enhancing the care of critically ill patients.A notable aspect is the more nuanced approach to early mobilization, which is recommended to commence within the first 72 hours of ICU admission. A staged concept and score-based mobilization schema facilitate improved patient rehabilitation. Mobilization should be standard of care, i.e., immobilization should be ordered by the physician. The guideline provides suggestions for the duration and additional mobilization measures to ensure patients stand, transfer actively from bed to chair, or walk as frequently as possible. These recommendations apply even during ECMO therapy, highlighting the importance of early mobilization.Further updates include semi-recumbent positions of at least 40° in intubated patients, with careful consideration of potential side effects. Continuous lateral rotation therapy (CLRT) is not advised due to the progress in intensive care therapy, shifting from deep sedation toward responsive patient management.Prone positioning (PP) involves rotating the patient 180° onto the ventral side. It is recommended as a therapeutic option for invasively ventilated patients with ARDS and impaired arterial oxygenation (PaO2/FiO2 <150mmHg), with a recommended minimum duration of 12 hours, ideally 16 hours. Special recommendations apply, for example, to COVID-19 patients with acute hypoxemic respiratory failure, where awake proning should be considered.Additionally, new chapters have been introduced focusing on assistive devices and neuromuscular electrical stimulation.
<P>PROBLEM TO BE SOLVED: To obtain an aqueous ophthalmic composition thickened by a water-soluble macromolecular compound and having high viscosity stability in its long-term storage.  <P>SOLUTION: This ophthalmic composition is obtained by formulating (A) the thickened ophthalmic composition containing the water-soluble macromolecular compound with (B) at least one ingredient selected from dibutyl hydroxytoluene, butyl hydroxyanisole, ascorbic acid or a salt thereof and a sulfite. The thickened ophthalmic composition containing the water-soluble macromolecular compound is filled in a resin-made container and then sealed in a packaging body. The concentration of innert gas in a space formed between the container and the packaging body is regulated to be ≥50 vol%. Or, the container filled with the thickened ophthalmic composition containing the water-soluble macromolecular compound is sealed is the packaging body together with a deoxidation agent.  <P>COPYRIGHT: (C)2004,JPO
Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
PURPOSE:To obtain a new cosmetic effective as an anti-sunburn cream or for preventing stain and freckle, having both absorbing effect on ultraviolet rays and inhibitory effect on tyrosinase, comprising a specific anthranilic acid and an Nalkylanthranilic acid. CONSTITUTION:A cosmetic comprises a compound of the formula (R is H or lower alkyl) (e.g. anthranilic acid or N-methylanthranilic acid) as an active ingredient, has extremely excellent UV-A absorbing ability and inhibitory effect on tyrosinase. Anthranilic acid, for example, is readily obtained by reducing o-nitro-or o-nitrosobenzoic acid or boiling o-nitrotoluene with alcoholic sodium hydroxide. The N-alkylanthranilic acid is prepared by N-alkylating anthranilic acid. Anthranilic acid is a metabolic intermediate for tryptophan and has extremely high safety.
OBJECTIVE: This study aimed to explore the therapeutic potential of human induced pluripotent stem cell (hiPSC)-derived cardiac tissues (HiCTs) in the emerging approach of bridge to recovery for severe heart failure with ventricular assist devices. We used a rat model of heterotopic heart transplantation (HTx) to mimic ventricular assist device support and heart unloading.
METHODS: HiCTs were created by inserting gelatin hydrogel microspheres between cell sheets made from hiPSC-derived cardiovascular cells. Male athymic nude rats underwent myocardial infarction (MI) and were divided into the following groups: MI (loaded, untreated control), MI + HTx (unloaded, untreated control), MI + HTx + HiCT (unloaded, treated), and MI + HiCT (loaded, treated). HiCTs were placed on the epicardium of the heart in treated groups. We evaluated HiCT engraftment, fibrosis, and neovascularization using histologic analysis.
RESULTS: After 4 weeks, HiCTs successfully engrafted in 5 of 6 rats in the MI + HTx + HiCT group (83.3%). The engrafted HiCT area was greater under unloaded conditions (MI + HTx + HiCT) than loaded conditions (MI + HiCT) (P < .05). MI + HTx + HiCT had a significantly smaller infarct area compared with MI and MI + HTx. The MI + HTx + MiCT group exhibited greater vascular density in the border zone than MI and MI + HTx. HiCT treatment suppressed cardiomyocyte atrophy due to left ventricular unloading (P = .001). The protein level of muscle-specific RING finger 1, an atrophy-related ubiquitin ligase, was lower in the MI + HTx + HiCT group than in MI + HTx (P = .036).
CONCLUSIONS: Transplanting HiCTs into ischemic hearts under unloaded conditions promoted engraftment, neovascularization, attenuated infarct remodeling, and suppressed myocyte atrophy. These results suggest that HiCT treatment could contribute to future advancements in bridge to recovery.
ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have shown efficacy in improving cardiovascular outcomes in patients with chronic heart failure (HF). However, their impact on HF patients with varying body mass index (BMI) levels remains uncertain. To explore potential interactions between baseline BMI and the cardiovascular benefits of SGLT-2 inhibitors, we conducted a systematic review of studies from PubMed, Scopus, and the Cochrane Library database spanning from inception to March 2024. Eligible studies reported cardiovascular outcomes according to baseline BMI in HF patients treated with SGLT-2 inhibitors. Ultimately, our analysis included 4 studies encompassing 20,723 patients. We conducted separate random-effects meta-analyses for the composite outcome of first hospitalization for HF (HHF) or cardiovascular death (CVD), total HHF, CVD, and all-cause mortality. Compared with placebo, SGLT-2 inhibitors significantly reduced the risk of the composite outcome of first HHF or CVD (hazard ratio = 0.78, 95% confidence interval: 0.72-0.83) and total HHF (hazard ratio = 0.73, 95% confidence interval: 0.61-0.83), with consistent effects observed across different BMI categories (test for subgroup differences: P = 0.63 and P = 0.56, respectively). Furthermore, no statistical heterogeneity was found in the effects of SGLT-2 inhibitors on CVD ( P = 0.84, I 2 = 0%) and all-cause mortality ( P = 0.52, I 2 = 0%) across each baseline BMI subgroup in patients with HF. No significant difference in safety was found between the placebo and SGLT-2 inhibitor arms. In conclusion, our findings suggest that the cardiovascular benefits of SGLT-2 inhibitors seem to be independent of baseline BMI in patients with HF.
Randomized cross-over design in 15 moderately active non-employee participants. 90 minutes of standard cycling exercise trial in heat chamber. TOI signals will obtain blood flow patterns from the face to compare against reference methods of dehydration including body mass, urine specific gravity, urine color, and thirst.
Habitual consumption of coffee may have substantial beneficial effects on glucose metabolism according to recent findings of epidemiological studies in the U.S., Europe, and Japan. However, data from longer-term human intervention studies with appropriate outcome measures are lacking. We will study the effects of caffeinated and decaffeinated coffee consumption on body fatness, insulin sensitivity and glucose tolerance that may underlie the observed associations with a lower risk of type 2 diabetes in a randomized controlled trial. We hypothesize that both caffeinated and decaffeinated coffee will improve insulin sensitivity and glucose tolerance. Before starting a larger, long-term intervention study, we will conduct a pilot study to test the feasibility of such a trial. The pilot study will be an 8-week parallel trial in 45 overweight individuals, who will be randomized to drinking 5 cups per day of 1) caffeinated coffee (n=15), 2) decaffeinated coffee (n=15), or 3) water (n=15). Body fatness (weight, waist circumference, bioelectrical impedance), insulin sensitivity (HOMA model), and glucose tolerance (oral glucose tolerance test) will be the primary outcomes. We will assess the adherence of participants to their assigned treatment by measuring serum caffeine concentrations, documentation of coffee use in diaries by the participants, and counting unused coffee packets. We will also obtain feedback from participants on how to improve compliance in a future trial. If successful, this study will form the basis for a definitive trial of coffee consumption, body fatness, and glucose tolerance. Given the extensive use of coffee and the rapidly increasing health burden of type 2 diabetes, such a trial would have important public health implications.
Many chemotherapeutic agents compromise the integrity of the mucosal barrier in the gut, allowing translocation of gram-positive bacteria in secondary lymphoid organs. While this has, until recently, been considered an undesirable side-effect, it may also represent one mechanism by which chemotherapy stimulates an effective anti-cancer immune response. The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria and other microorganisms living in the gut. In turn, the activities of these immune cells could work with anti-cancer therapies to make them more, or less, effective. The hypothesis is that gut microbial composition can influence immune response to the tumor, resulting in inter-individual differences in the response to anti-cancer therapies.
Patients should be advised to take Macrobid with food (ideally breakfast and dinner) to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy.

Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking Macrobid.

Patients should be counseled that antibacterial drugs including Macrobid should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Macrobid is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Macrobid or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
The effect of laser stimulation, e.g., R:GEN, of the RPE and its impact on MMPs and RAAS pathways are used to guide patient therapies. Certain biomarkers, namely MMPs, TIMPs, and components associated with RAAS, are effective indicators of healing response levels generated by the patients undergoing the therapy. An eye disease is diagnosed in a patient and a first biomarker sample is obtained from a biomatrix, e.g., patient's blood in containers with protease inhibitors. An initial subthreshold laser treatment is then performed on the eye. By monitoring the presence, amount, and relative levels of one or more of the above biomarkers as the patient heals, it is determined when the patient's body has sufficiently responded to the previous treatment, such that retreatment may be appropriate. The present disclosure demonstrates effective treatment of eye diseases, e.g., dry age-related macular degeneration, which utilize laser treatment alone or in combination with other treatments.
The present invention relates to a colour-restoring ointment for treating burn and scald, containing (by weight) 800-1200 portions of sesame oil, 200-300 portions of minium and 4-8 portions of beewax. Its preparation process is as follows, the sesame oil is heated in iron pan, and then the beewax is added when the temp. reaches 40-50 deg.C, and the minium is added when the temp. reaches 120 deg.C and the heating is stopped. The above-mentioned materials are stirred until the colour of the mixture is changed from orange to black, and the mixture is screened by using screen whose mesh size is 147 microns when the oil temp. is lowered to 80 deg.C. When the oil temp. is lowered to room temp. the mixture is uniformly stirred, and packaged, so that the invented finished product can be obtained.
PROBLEM TO BE SOLVED: To obtain a solution of a high concentration having a long-term storability comprising 2,5-diaminotoluene, and ascorbic acid or thioglycolic acid (salt) each in a specific amount and an aqueous medium. SOLUTION: The objective 2,5-diaminotoluene composition comprises at least 51 wt.% of 2,5-diaminotoluene, at least 0.5 wt.% of a reducing matter selected from ascorbic acid, thioglycolic acid and salts thereof, and an aqueous medium. The content of 2,5-diaminotoluene is, from the viewpoint of the solubility, preferably 51-80 wt.%, more preferably 51-60 wt.%, though a higher concentration is desirable from transportation and storage cost standpoints. The content of the reducing agent is preferably 0.5-5 wt.%. As the aqueous media, there can be exemplified water, lower alcohols such as ethanol, propanol and the like, and water is preferable. The content thereof is appropriately determined according to the amount of 2,5-diaminotoluene and the reducing agent employed.
Disclosed herein are consumable products for pets such as dogs, cats, horses, and birds the consumable products containing a cannabinoid. The consumable products disclosed herein can be formulated as chews or liquid supplements with pleasing flavors in order to encourage the pets to eat the consumable products and derive therapeutic benefits from consumption. The consumable products contain live, active cultures of probiotic microorganisms or may contain spores of probiotic microorganisms. The consumable products have anti-inflammatory effects due to the presence of the cannabinoid but are non-narcotic. Further, the consumable products serve to enhance gut health due to the presence of probiotics. The consumable products are particularly useful for treating, preventing, and eliminating side effects from various diseases and conditions as well as side effects from medication use. In some aspects, the consumable products are co-administered or co-formulated with other therapeutic agents.
Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
Systems, methods, and instrumentalities are disclosed for data processing and creating a record of the processing for archival in metadata associated with the results of the processing. The processing may include transformations of the data. Transforming the data may generate transformed data. The processes performed may be archived, for example, in metadata associated with the transformed data. The metadata may be annotated with information associated with previous transforms performed on the transformed data. The metadata may be stored with the transformed data.
BACKGROUND: This study investigates the gap in understanding the dynamics of recurring disease activity (RDA) in RRMS patients after fingolimod (FGL) treatment discontinuation. The aim is to investigate RDA in RRMS patients after stopping FGL, aiming to improve management and comprehension of disease progression post-treatment.
METHODS: In this multicenter, retrospective study, data from 172 of 944 RRMS patients aged 18-55, across nine centers in Turkey, who discontinued FGL treatment, were analyzed. The collected data included EDSS scores, annualized relapse rates (ARR), lymphocyte counts, and MRI findings, with follow-up assessments conducted at 6 months, 1 year, and up to 2 years.
RESULTS: RDA was observed in 31.9 % of patients, with incidences of rebound and reactivation at 20.3 % and 11.6 %, respectively. Factors like younger age, longer treatment duration, lower lymphocyte counts, and higher lesion burden increased RDA risk. Notably, 52.9 % of pregnant patients experienced RDA (16.4 % of the overall RDA group), with rebound occurring in six and reactivation in three. Patients with RDA had longer medication-free intervals and increased ARR. Discontinuation reasons varied, with disease progression linked to a lower RDA risk.
CONCLUSION: Findings highlight the necessity for personalized management and vigilant monitoring after FGL discontinuation in RRMS patients, offering critical insights into RDA risk factors, and the complex interplay between treatment cessation, pregnancy, and disease progression.